Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 25,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 25,000 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $49.77, for a total value of $1,244,250.00. Following the sale, the chief executive officer now directly owns 462,680 shares of the company’s stock, valued at $23,027,583.60. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Andrew Cheng also recently made the following trade(s):

• On Monday, July 3rd, Andrew Cheng sold 25,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.88, for a total transaction of $1,122,000.00.

Akero Therapeutics Trading Up 0.0 %

Shares of NASDAQ:AKRO opened at $52.25 on Tuesday. The company has a market cap of $2.91 billion, a P/E ratio of -20.41 and a beta of -0.94. The stock’s 50-day moving average is $46.43 and its 200-day moving average is $45.30. Akero Therapeutics, Inc. has a 52-week low of $25.21 and a 52-week high of $58.38. The company has a debt-to-equity ratio of 0.04, a quick ratio of 29.78 and a current ratio of 29.77.

Akero Therapeutics (NASDAQ:AKRO) last announced its earnings results on Friday, August 11th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.01. Equities research analysts predict that Akero Therapeutics, Inc. will post -2.75 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. HC Wainwright raised their price target on shares of Akero Therapeutics from $62.00 to $64.00 in a report on Wednesday, June 7th. UBS Group began coverage on shares of Akero Therapeutics in a report on Monday, August 28th. They set a “buy” rating and a $83.00 price target on the stock. Evercore ISI increased their price target on Akero Therapeutics from $50.00 to $60.00 and gave the company an “outperform” rating in a report on Wednesday, September 13th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Akero Therapeutics from $49.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 5th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $65.33.

Hedge Funds Weigh In On Akero Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Hong Kong Ltd bought a new position in Akero Therapeutics during the first quarter worth $32,000. Osaic Holdings Inc. raised its holdings in Akero Therapeutics by 24.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,809 shares of the company’s stock valued at $84,000 after acquiring an additional 359 shares in the last quarter. Royal Bank of Canada raised its holdings in Akero Therapeutics by 9.9% in the 3rd quarter. Royal Bank of Canada now owns 2,605 shares of the company’s stock valued at $89,000 after acquiring an additional 235 shares in the last quarter. Quantbot Technologies LP raised its holdings in Akero Therapeutics by 616.8% in the 2nd quarter. Quantbot Technologies LP now owns 10,100 shares of the company’s stock valued at $95,000 after acquiring an additional 8,691 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in Akero Therapeutics by 104.5% in the 4th quarter. Wells Fargo & Company MN now owns 1,817 shares of the company’s stock valued at $100,000 after acquiring an additional 42,582 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.